Jazz Pharmaceuticals Plc meldet Patent für CBD-Präparat mit 90 % CBD und THC an – Medical Marijuana Program Connection

Laut dem Unternehmensprofil von GlobalData am Jazz Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Jazz PharmaceuticalsDer Zuschussanteil betrug im Februar 2024 47 %. Der Zuteilungsanteil basiert auf dem Verhältnis der Anzahl der Zuteilungen zur Gesamtzahl der Patente.

Cbd preparation with at least 90% cbd and thc

A recently granted patent (Publication Number: US11865102B2) discloses a cannabidiol (CBD) preparation with a high concentration of CBD, greater than or equal to 90% (w/w) based on the total amount of cannabinoids in the preparation. The remaining cannabinoids in the preparation include tetrahydrocannabinol (THC), present as a mixture of trans-THC and cis-THC, with a specific ratio ranging from about 0.7:1.0 to about 5.0:1.0. Additionally, the CBD preparation contains not more than 1.5% (w/w) THC, with specific ranges of THC content specified in the claims.

Furthermore, the patent covers the use of this CBD preparation in pharmaceutical compositions for treating epilepsy, specifically targeting conditions such as Dravet syndrome, Lennox Gastaut syndrome, Doose syndrome, or tuberous sclerosis complex (TSC). The method involves administering a therapeutically effective amount of the CBD preparation, with specified dosage ranges from about 5 mg/kg/day to…